The rate of adoption of In Silico Trials among medical technology companies is still very low, and we believe a major reason is the lack of culture and skills.
To help the companies to best engage with this potentially disruptive innovation, our team, in close collaboration with an extensive international community of experts, has developed educational initiatives both for students and professionals.
